Following the discovery of interleukin (IL)-17 producing T helper (Th17) cells as a distinct lineage of CD4+ T helper cells it became clear that these cells play an important role in the host defense against
Introduction
Type 1 diabetes (T1D) is a T cell mediated autoimmune disease in which insulin producing β cells are selectively destroyed in the pancreatic islets of Langerhans. Both CD4 and CD8 T cells have been implicated in T1D and the disease pathogenesis is primarily driven by CD4+ Th1 (T helper type 1) cells 1 . Several studies including our own have shown that CD4+CD25+ regulatory T cells (Treg) induced by various immunotherapy approaches are strongly protective in the NOD (non-obese diabetic) mouse model of T1D and in human subjects [2] [3] [4] . The pathogenic role of Th17 cells has been implicated in many autoimmune diseases but direct evidence supporting their involvement in T1D pathogenesis is lacking [5] [6] [7] . were pathogenic upon adoptive transfer into NOD mice causing type 1 diabetes while cells induced by TGF-β plus IL-6 (termed as Treg17 cells) were protective and suppressed the pathogenic T cells. The Teff17 cells differentially secreted granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-22 while Treg17 cells produced increased levels of IL-10 and IL-21 (Fig.) . The identification of two distinct Th17 populations one with pathogenic properties (Teff17) and another with regulatory and protective properties (Treg17) may explain the controversial nature of Th17 cells in autoimmunity particularly T1D.
Plasticity of Th17 cells
To determine the adoptive transfer capacity of Th17 cells in T1D two different approaches were used. The TGF-β plus IL-6 polarized Th17 cells when transferred into wild type NOD mice promoted pancreatic inflammation but no overt diabetes [6] [7] [8] . In lymphopenic NODSCID (severe combined immunodeficiency) recipients Th17 cells mediated transfer of T1D but this was due to the plasticity of Th17 cells. It was found that Th17 cells converted into IFN-γ producing Th1 cells in the lymphopenic environment of NOD.SCID mice 21 . Th17 cells generated in vivo have been found to co-produce IL-17 and IFN-γ and these cells express Th1 transcription factor T-bet in addition to RORγT. 
IL23 promotes effector pathogenic Th17 cells
IL-23 appears to be the key player in the terminal differentiation of Th17 cells and generation of pathogenic Th17 cells (Fig.) 12,23
. Treg17 cells can be converted to Teff17 cells by culturing with IL-23 in vitro. Several investigators have shown that TGF-β plus IL-6 induced Th17 cells produce IL-17 but do not transfer autoimmunity. IL-23 is required for these cells to acquire a pathogenic phenotype 10, 12, 24 . This supports the results that IL-23 and IL-23R deficient mice are highly resistant to autoimmune diseases 24 . IL-23 has emerged as the key factor in determining if Th17 cells can become pathogenic during the differentiation process. This also influences the expression of pathogenic cytokines particularly GM-CSF. This effector phenotype is a result of the network of transcription factors that include RORγT, T-bet and FoxP3. Treg17 cells produce variable amounts of IL-10 and IL-23 which diminish IL-10 production by Th17 cells while TGF-β promotes the production of IL-10 25,26 . GM-CSF is important for the pathogenicity of Th17 cells and TGF-β suppresses its production 27, 28 . The proinflammatory cytokines IL-1β and IL-23 drive the production of pathogenic cytokine GM-CSF. A recent study has confirmed that IL-23-induced GM-CSF is essential for the pathogenicity of Th17 cells in the autoimmune model of multiple sclerosis (MS) namely experimental autoimmune encephalomyelitis (EAE) 24 . Moreover, Th17 cells that lack the ability to produce GM-CSF do not transfer autoimmune disease 28 . Thus the effector function of Teff17 cells is driven by GM-CSF via IL-23, and IL-10 drives the effector function of Treg17 cells via TGF-β. In summary, high TGF-β levels contribute to the maturation of Treg17 cells and IL-23 supports induction of Teff17 cells in autoimmunity.
Conclusion
The initial focus of Th17 studies was to determine their pathogenic role in inflammatory and autoimmune diseases. In the case of T1D, the published work has provided conflicting results either supporting their role in the destruction of islet β cells or having no effect or protecting animals from adoptive transfer of disease. Recent studies support the regulatory function of Th17 cells induced by mycobacterial adjuvants i.e. BCG and CFA. The in vitro conditions used for the generation of the Th17 cells for these studies contribute to the functional differences observed by various investigators. The Th17 subsets induced by TGF-β and IL-6 and/or IL-23 produce immunosuppressive to proinflammatory cytokines. In addition, the plasticity of Th17 cells has been discovered where these can give rise to Th1 cells in vivo. Immunization with adjuvants suggests that it is possible to change the functional phenotype of Th17 cells from pathogenic to protective by altering the cytokine microenvironment. This may also be feasible by immunization with autoantigens to modulate autoimmune diseases. In summary, the role of Th17 cells in autoimmune diseases is not simply to be proinflammatory and cause tissue damage but these can also act in an immunoregulatory fashion leading to prevention of autoimmunity by inhibiting pathogenic T cells.
